Nociceptin/orphanin FQ increases anxiety-related behavior and circulating levels of corticosterone during neophobic tests of anxiety.
Intracranial administration of nociceptin/orphanin FQ (N/OFQ) increases circulating concentrations of adrenocorticotrophic hormone and corticosterone in unstressed rats, and elevates the responsiveness of these hormones during mild stress. Furthermore, N/OFQ and its cognate receptor are both abundant in a variety of limbic nuclei, and stress exposure decreases neuronal N/OFQ content in forebrain neurons. In light of these and other findings, we examined the potential involvement of N/OFQ in regulation of anxiety-related behaviors in rats. In the open field, elevated plus maze, and dark-light neophobic tests, intracerebroventricular N/OFQ (1.0 pmole-1.0 nmole) increased the expression of anxiety-related behaviors. Specifically, N/OFQ increased the latency to enter, decreased the number of entries into, and decreased the time spent in the exposed or brightly lit environments of all three tests. N/OFQ also enhanced thigmotactic responses in the open field test. The effects of diazepam and of the benzodiazepine inverse agonist FG 7142 were also assessed in independent groups of rats. In all three tests, the behavioral effects of N/OFQ resembled the anxiogenic actions of FG 7142, and contrasted with the anxiolytic actions of diazepam. N/OFQ administration also increased circulating concentrations of corticosterone during anxiety testing, in comparison with the concentrations in vehicle-treated controls. We conclude that N/OFQ administration is anxiogenic, and elevates responsiveness of the hypothalamic pituitary-adrenal axis during neophobic tests of anxiety. This supports the possibility that N/OFQ neurotransmission participates in processing of emotionally-salient and stressful stimuli, and suggests that normal functioning of the N/OFQ system may be important in physiological and psychological well-being.
Fernandez
Fabian
F
Department of Psychology, University of Florida, Gainesville, FL 32611-2250, USA.
Misilmeri
Michael A
MA
Felger
Jennifer C
JC
Devine
Darragh P
DP
D000704:Analysis of Variance; D000818:Animals; D014151:Anti-Anxiety Agents / Q000494:pharmacology; D001007:Anxiety / Q000097:blood* / Q000503:physiopathology; D001522:Behavior, Animal / Q000187:drug effects*; D002243:Carbolines / Q000494:pharmacology; D003345:Corticosterone / Q000097:blood*; D003624:Darkness; D003975:Diazepam / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004333:Drug Administration Routes; D005106:Exploratory Behavior / Q000187:drug effects; D018756:GABA Antagonists / Q000494:pharmacology; D008027:Light; D008297:Male; D018782:Maze Learning / Q000187:drug effects; D009483:Neuropsychological Tests; D018847:Opioid Peptides / Q000494:pharmacology*; D011863:Radioimmunoassay; D051381:Rats; D020318:Rats, Long-Evans; D011930:Reaction Time / Q000187:drug effects; D013315:Stress, Psychological; D014743:Videotape Recording; D000097629:Nociceptin
D014151:Anti-Anxiety Agents; D002243:Carbolines; D003345:Corticosterone; D003975:Diazepam; D018756:GABA Antagonists; D018847:Opioid Peptides; D000097629:Nociceptin; C035874:FG 7142